GDTC Valuation

CytoMed Therapeutics Ltd

Add to Watchlist

Advanced Chart

1.930

+0.065(3.485%)1D

Overview
Forecast
Valuation
Earnings

GDTC Relative Valuation

GDTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GDTC is overvalued; if below, it's undervalued.

Historical Valuation

CytoMed Therapeutics Ltd (GDTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.57. The fair price of CytoMed Therapeutics Ltd (GDTC) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.93

Fair

-11.35

Trailing

Forward

0.00

EV/EBITDA

CytoMed Therapeutics Ltd. (GDTC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-9.90

EV/EBIT

CytoMed Therapeutics Ltd. (GDTC) has a current EV/EBIT of -9.90. The 5-year average EV/EBIT is -15.38. The thresholds are as follows: Strongly Undervalued below -27.36, Undervalued between -27.36 and -21.37, Fairly Valued between -9.38 and -21.37, Overvalued between -9.38 and -3.39, and Strongly Overvalued above -3.39. The current Forward EV/EBIT of -9.90 falls within the Historic Trend Line -Fairly Valued range.

41.39

CytoMed Therapeutics Ltd. (GDTC) has a current PS of 41.39. The 5-year average PS is 57.81. The thresholds are as follows: Strongly Undervalued below 22.36, Undervalued between 22.36 and 40.09, Fairly Valued between 75.54 and 40.09, Overvalued between 75.54 and 93.26, and Strongly Overvalued above 93.26. The current Forward PS of 41.39 falls within the Historic Trend Line -Fairly Valued range.

-13.14

P/OCF

CytoMed Therapeutics Ltd. (GDTC) has a current P/OCF of -13.14. The 5-year average P/OCF is -18.78. The thresholds are as follows: Strongly Undervalued below -29.98, Undervalued between -29.98 and -24.38, Fairly Valued between -13.18 and -24.38, Overvalued between -13.18 and -7.58, and Strongly Overvalued above -7.58. The current Forward P/OCF of -13.14 falls within the Overvalued range.

0.00

P/FCF

CytoMed Therapeutics Ltd. (GDTC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

CytoMed Therapeutics Ltd (GDTC) has a current Price-to-Book (P/B) ratio of 3.19. Compared to its 3-year average P/B ratio of 3.80 , the current P/B ratio is approximately -15.97% higher. Relative to its 5-year average P/B ratio of 3.80, the current P/B ratio is about -15.97% higher. CytoMed Therapeutics Ltd (GDTC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -9.25%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -9.25% , the current FCF yield is about -100.00% lower.

3.19

P/B

Median3y

3.80

Median5y

3.80

-14.87

FCF Yield

Median3y

-9.25

Median5y

-9.25

Competitors Valuation Multiple

The average P/S ratio for GDTC's competitors is 0.00, providing a benchmark for relative valuation. CytoMed Therapeutics Ltd Corp (GDTC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GDTC.O

CytoMed Therapeutics Ltd

ProMIS Neurosciences Inc

Loss

22.22M

Performance Decomposition

Market capitalization of GDTC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GDTC in the past 1 year is driven by Unknown.